No Data
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
Theralase Technologies Inc: INTERIM MDA EN
Theralase Technologies Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Theralase Technologies Raises $4.8 Million Via Brokered Private Placement Offering
Earnings Call Summary | Theralase Technologies Inc(TLT.CA) Q4 2025 Earnings Conference
Theralase Technologies Inc: MDA EN